# A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

> **NCT04554914** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pierre Fabre Medicament** · enrollment: 190 (estimated)

## Conditions studied

- Epstein-Barr Virus (EBV)-Associated Diseases
- EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
- EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)
- EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
- EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Solid Organ Transplant Complications
- Lymphoproliferative Disorders
- Allogeneic Hematopoietic Cell Transplant
- Stem Cell Transplant Complications
- EBV+ Sarcomas
- Leiomyosarcoma

## Interventions

- **BIOLOGICAL:** Tabelecleucel

## Key facts

- **NCT ID:** NCT04554914
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-14
- **Primary completion:** 2027-06
- **Final completion:** 2028-05
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04554914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04554914, "A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04554914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*